Bluejay Diagnostics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.6M
- Price
- $0.8107
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.50%
- Volume
- 6.9M
About
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Quick stats
Shares outstanding4.5M
Computed float4.4M
Float / shares98.0%
Cash runway (months)16
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001704287
Websitehttps://bluejaydx.com
AI Summary
AI-generated1/12
minorneutralclinical trial
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Bluejay Diagnostics disclosed baseline clinical characteristics from its SYMON-II validation study, covering 777 evaluable sepsis and septic shock patients with 140 28-day non-survivors, an approximately 18% 28-day mortality rate.
The dataset shows meaningful disease severity, with 39.5% meeting Sepsis-3 septic shock criteria and non-survivors showing septic shock at 56.4% versus 35.8% in survivors.
The release is a data-expectation setting step, not a result: baseline figures do not establish IL-6 prognostic performance or regulatory acceptability, which await completion of planned analyses supporting a future 510(k) filing. The Symphony IL-6 Test has no FDA clearance and is not commercially available in the U.S.
Red flags
- Symphony IL-6 Test is not FDA cleared or approved and has no commercial availability
- Baseline data do not establish prognostic performance or regulatory acceptability; pivotal IL-6 results still pending
- Pre-revenue company dependent on a single lead product candidate